Thanatos-associated protein domain containing, apoptosis-associated protein 1 (THAP1), the gene mutated in DYT6 dystonia, encodes a transcription factor. While the N-terminal THAP domain allows for specific DNA-binding, the functional relevance of the other regions is largely unknown. The C-terminus contains a 4-amino-acid-spanning host cell factor 1 (HCFC1)-binding domain (HBM) that mediates the interaction with HCFC1. Interestingly, three mutations affecting the HBM (p.N136S, p.N136K, p.Y137C) have been reported in dystonia patients. We investigated the consequences of these mutations on the interaction of THAP1 with HCFC1 and demonstrated that all three mutations abolished HCFC1-THAP1 complex formation. Notably, HCFC1 co-localization was found in >90% of the almost 3,500 chromatin regions loaded with THAP1 in publicly available genomewide ChIP data. By siRNA-mediated depletion of HCFC1, we detected an increase of THAP1 expression, indicating a co-repressor activity of HCFC1 for THAP1. Quantitative ChIP on selected promoters revealed that none of the mutations significantly decreased the DNA-binding ability of THAP1 while HCFC1 binding was highly reduced. Our findings indicate a THAP1-mediated recruitment of HCFC1 to THAP1 target sites. Of note, dystonia-causing mutations within the HBM in THAP1 abolished this interaction. Thus, we demonstrate disrupted THAP1-HCFC1 complex formation as another mechanism of dystonia-causing mutations leading to transcriptional dysregulation.
Introduction
Mutations in the gene Thanatos-associated protein (THAP) domain containing, apoptosis-associated protein 1 (THAP1) were repeatedly found as a cause of DYT6 dystonia (now referred to as DYT-THAP1) (1) . This type of dystonia is characterized by early-onset, isolated torsion dystonia with prominent cranio-cervical and upper limb muscle involvement (2) (3) (4) (5) . Speech impairment due to laryngeal dystonia is common among patients. The THAP1 gene encodes a transcription factor that was shown to autoregulate its own expression (6) as well as a number of target genes including RRM1 and BIRC5 (7) . In addition, we and others demonstrated in vitro that THAP1 binds to the promoter of TOR1A, the gene mutated in DYT1 dystonia (DYT-TOR1A), and represses TOR1A expression (8, 9) . Of note, in-vivo proof of THAP1-mediated repression of TOR1A in human or mouse cell lines is still warranted (8) (9) (10) .
THAP1 consists of 213 amino acids and its DNA-binding properties are associated with the N-terminal THAP domain (amino acids 1-91) representing a zinc-finger structure (11, 12) . Towards the C-terminus, THAP1 contains a proline-rich region (amino acids 96-108) and a coiled-coil domain (amino acids 139-190) with a nuclear localization signal (NLS, amino acids 147-162). To date, more than 90 missense, nonsense and frameshift mutations in THAP1 have been described in dystonia patients of different ethnicities (3, 5, 13) . Most of these mutations affect the N-terminal part of the protein thought to impair THAP domain-mediated activities such as DNA-binding (14) . However, the functional consequences of missense mutations affecting the C-terminal region of THAP1 are rather unknown. The coordinated activity of transcription factors is regulated by the dynamic interaction with different cofactors. These interactions are facilitated by certain binding motifs to recruit specific binding partners. One important chromatin-associated transcriptional co-regulator is the host cell factor-1 (HCFC1, also referred to as C1, VCAF, CFF, HCF1) which is involved in a broad range of cellular functions. Of note, it has previously been shown that all THAP proteins with the exception of THAP8 and THAP10 carry at least one four-amino-acid-spanning HCFC1-binding motif (HBM) (11) . In THAP1, this motif is formed by amino acids 134 to 137.
The HBM allows recruitment of the transcriptional cofactor HCFC1 which was first identified as an essential component in a gene enhancer complex activating the herpes simplex virus immediate-early genes (15) (16) (17) (18) . HCFC1 is expressed as a 2035-amino acid precursor which is proteolytically cleaved at one of six highly specific cleavage sites, resulting in a non-covalently bound complex of an N-terminal chain and the corresponding C-terminal chain (19, 20) . Both regions include several functional domains. The C-terminal chain contains a nuclear localization signal, a fibronectin-like motif and a transcriptional activation domain. The N-terminal chain includes five kelch repeats, following referred to as the kelch-domain. This kelch domain has a six-bladed b-propeller structure that mediates protein binding to the HBM.
In this study, we investigated the consequences of dystoniacausing mutations in THAP1 on THAP1-HCFC1 complex formation and its relevance for THAP1-mediated transcriptional regulation. Yeast-two-hybrid and immunoprecipitation assays were used to study direct protein-protein interactions, while chromatin immunoprecipitation (ChIP) followed by quantitative PCR (ChIP-qPCR) was applied to investigate DNA binding of wildtype and mutant THAP1 as well as HCFC1. Moreover, in-silico analyses using genome-wide ChIP-seq datasets demonstrated that more than 90% of about 3,500 THAP1 binding sites overlap with HCFC1 binding sites underlining the overall importance of HCFC1 in regulating THAP1 activity.
Results

Dystonia-causing mutations impair THAP1-HCFC1 complex formation
HCFC1 was reported to interact with different proteins of the THAP family including THAP1. This interaction is mediated by the highly conserved HBM. To date, three dystonia causing mutations in THAP1 have been reported within the HBM domain: p.N136S (21) , p.N136K (22) and p.Y137C (23) . We hypothesized that these mutations may impair THAP1-HCFC1 interaction (Fig. 1A) .
In a first step, we used a yeast-two-hybrid assay to verify the interaction of THAP1 and HCFC1. For this, we investigated growth of yeast cells transformed with THAP1 fused to a transcriptional activation domain and the kelch domain of HCFC1 fused to a DNA-binding domain on -4SD medium. These selective conditions only allow yeast growth if THAP1 interacts with HCFC1. We demonstrated that yeast cells transformed with wildtype THAP1 and HCFC1 grew on -4SD medium while cells containing empty control plasmids did not grow under -4SD selection, pointing to a specific interaction of THAP1 with HCFC1 (Fig. 1B, lower panel, first and second row) .
Next, we were interested whether THAP1 mutations impair this interaction. Therefore, THAP1 expression constructs containing each one of the three DYT6-causing mutations within the HBM of THAP1 (aa 134-137) were generated by site-directed mutagenesis. None of the yeast cells co-transformed with HCFC1 and a mutant form of THAP1 did grow on -4SD plates despite confirmed expression of the constructs by Western blot analyses (data not shown). This indicated a loss of THAP1-HCFC1 complex formation due to the THAP1 mutations (Fig. 1B) . To confirm our data obtained from two-hybrid analyses in yeast cells, we performed co-immunoprecipitation of THAP1-HCFC1 protein complexes in human cells (HEK293). To test the consequences of all three missense mutations, cells were transiently transfected with wildtype or mutant FLAG-tagged THAP1 expression constructs. Endogenous HCFC1 protein complexes were precipitated, separated by SDS-PAGE and analyzed by Western blotting using an anti-FLAG antibody. While a distinct signal of the wildtype THAP1 protein was detected in the HCFC1 precipitates, mutant THAP1 was not efficiently co-precipitated with HCFC1 (Fig. 1C) . Equal expression of all THAP1 expression constructs as well as proper precipitation of HCFC1 was evaluated by Western blotting.
siRNA-mediated repression of HCFC1 increases THAP1-activity
To investigate the role of HCFC1 as a cofactor of THAP1, we used siRNA to knock down HCFC1 expression and investigated THAP1 activity by analyzing expression of autoregulated THAP1. The siRNA-mediated knock-down of HCFC1 protein and cleaved HCFC1 polypeptides (19, 20) was confirmed by Western blotting ( Fig. 2A) . We observed a significant increase of endogenous THAP1 levels in SH-SY5Y cells in which HCFC1 expression was highly reduced (Fig. 2B ).
Dystonia-causing mutations affect THAP1-mediated recruitment of HCFC1 to different THAP1-target promoters
While the N-terminal atypical zinc finger domain of THAP1 allows for specific DNA-binding, HCFC1 does not directly bind to DNA but it is recruited to its target promoters via interacting transcription factors. To investigate whether dystonia-causing variants within the HBM of THAP1 influence HCFC1 recruitment, ChIP experiments followed by quantitative PCR (ChIP-qPCR) were conducted.
For this, SH-SY5Y cells were transiently transfected with wildtype and mutant FLAG-tagged THAP1. Equal expression of THAP1 proteins was verified by Western blot analysis (Fig. 2C) . Precipitated DNA fragments were quantified by TaqMan assays. For quantitative PCR analysis, we selected four THAP1 target genes (THAP1, TOR1A, RRM1, and BIRC5) that have previously been identified by expression analyses or candidate approaches (6) (7) (8) and that showed a respective signal in publicly available genome-wide ChIP-Seq data (24) . We detected significantly reduced HCFC1-binding for all four analyzed THAP1 target promoters. Specifically, we found only 10-40% HCFC1 using the p.N136K THAP1 and 15-40% using the p.Y137C THAP1 when compared to the HCFC1 levels measured in cells transfected with wildtype THAP1 (Fig. 2D and E) .
As a control, we performed ChIP analyses with anti-FLAG M2 antibody (to precipitate THAP1 protein), to determine the DNAbinding abilities of mutant THAP1 (p.N136K and p.Y137C) compared to wildtype THAP1 protein. By this, we demonstrated that the DNA binding ability of THAP1 was not impaired since wildtype and mutant THAP1 were still able to bind to all four promoters. Of note, p.Y137C THAP1 protein even seemed to have an increased DNA-binding affinity (Fig. 2F ).
HCFC1 shares more than 90% of the THAP1-binding site in the genome
Based on our results that demonstrated THAP1-mediated recruitment of HCFC1 to selected gene promoters modulating THAP1 activity in gene regulation, a genome-wide in-silico analysis was performed to investigate the overlap of THAP1-and HCFC1 DNA binding sites in human cells.
Using publicly available genome-wide ChIP-seq data from K562 cells (24), we annotated a total of 3,469 independent THAP1-binding sites. The vast majority of genomic elements loaded with THAP1 also showed HCFC1 binding (92.6%/3,212 sites, Fig. 3A ). For HCFC1, we detected 42,132 unique binding sites in K562 cells; only 7.3% (3,212 sites) of which overlap with THAP1-binding sites. Co-binding of THAP1 and HCFC1 was mainly found within promoter regions (92.6%/2,975 sites), while only a minor fraction was located within gene bodies (3.6%/115 sites) or intergenic regions (3.8%/122 sites) (Fig. 3A) . As some promoter regions harbor multiple binding sites, the 2,975 THAP1 signals within promoters correspond to 2,811 different promoters. In contrast, those THAP1-binding sites that did not show HCFC1 co-binding were not enriched within promoter regions (Fig. 3A) .
Screening of dystonia patients for mutations in HCFC1
Since mutations in different partners from the same protein complex can lead to overlapping phenotypes (25), we tested 156 dystonia patients for mutations in HCFC1 in regions encoding domains important for the interaction with THAP1 (Exons 1-9, Exon 17, NM_005334 disease-causing mutation based on their frequency and/or in-silico prediction (Supplementary Table) .
Discussion
After the identification of mutations in THAP1 as a genetic cause of dystonia in 2009, more than 90 different mutations were reported in dystonia patients (3, 5, 13 ). These variants include many different types of mutations such as small deletions, insertions, nonsense, and missense variants that are spread over the entire gene. Missense mutations affecting specific residues within the encoded protein may be used to characterize protein functions. Interestingly, most of the disease-linked THAP1 missense variants cluster within the N-terminal THAP zinc finger Measurements were normalized to GAPDH and MAPK1. Data are based on triplicates in six independent runs and given as mean and range of variation. Asterisks indicate statistical significance compared to control siRNA (*P < 0.05, *** P<0.001, unpaired t-test) (C) SH-SY5Y cells were transiently transfected with THAP1 3xFLAG wildtype and mutant constructs and were analyzed by Western blotting 48h after transfection. All proteins are equally expressed and are stable. NPTII and GAPDH expression served as transfection and loading control. Untransfected cells were used as a negative control. (D-F) Quantitative ChIP assays performed with chromatin of wildtype or mutant THAP1-3xFLAG transfected SH-SY5Y cells with antibodies against HCFC1 (D,E) and anti-FLAG to test THAP1s DNA-binding ability (F). Cells transfected with empty FLAG vector served as control. Mean values of triplicates and range of variation are given. Results were derived from a single experiment that is representative of at least two independent experiments. The promoter enrichment was analysed relative to input. The qPCR analysis of ChIP-DNA was performed with specific TaqMan probes and primers for the THAP1, TOR1A, RRM1 and BIRC5 minimal promoter. At all analyzed promoter regions the THAP1 mutants p.N136K and p.Y137C showed a significant decrease of HCFC1 recruitment down to 10-40% for p.N136K and 15-40% for p.Y137C. Asterisks indicate statistical significance compared to wildtype THAP1 (*P<0.05, **P<0.01, ***P<0.001, unpaired t-test). (F) The two mutations affecting the HBM domain did not reduce the enrichment of THAP1 itself at any of the four tested promoter regions. For p.Y137C we observed a 3-fold higher DNA affinity at the THAP1 promoter, a 1.5-fold increase of the DNA-binding ability at the TOR1A promoter and a 2-fold increase at the RRM1 and BIRC5 promoters compared to wildtype THAP1. domain or within the C-terminal coiled-coil region. The THAP domain includes an atypical zinc-finger that specifically binds to the consensus motifs TxxxGGCA and/or TxxGGGx(A/T) referred to as THAP1-binding sequence (THABS) (26, 27) . With respect to variants within the THAP domain, it was shown that some mutations significantly reduce the DNA-binding ability, while others did not affect DNA binding or even increased the affinity of THAP1 to DNA (6, 12) . In contrast to the often well characterized mutations within the THAP domain, only little is known about the functional relevance of variants affecting the C-terminal region of THAP1. It has been suggested that these changes may impair THAP1 protein complex formation since coiled-coil domains are involved in protein-protein interactions (28) .
The HBM domain in THAP1 is highly conserved within the THAP family of transcription factors, indicating an important function of the THAP-HCFC1 interaction (11) . HCFC1 is a general transcriptional co-regulator involved in various different cellular mechanisms including cell cycle control and proliferation. Depending on their specific function, transcription factors are embedded into complexes together with cofactors, histonemodifiers and other proteins regulating promoter activity. The composition of these protein complexes is highly dynamic and specific for different tissues, functions and during distinct developmental stages (29) . HCFC1 may be involved in the regulation of more than one quarter of all human promoters (30) which is illustrated further by more than 42,000 genomic regions to which HCFC1 (indirectly) binds based on findings from a genome-wide ChIP-seq analysis (24) . Notably, numerous interaction partners have functionally been confirmed including THAP11, THAP3, YY1, and E2F1 (14, 11, 7, (31) (32) (33) . In this study, we focused on the interaction with THAP1 which is also suggested based on the genome-wide ChIP-seq data including data for THAP1 for K562 myelogenous leukemia cells: Of about 3,500 THAP1 DNA binding sites, more than 90% also showed binding of HCFC1. The vast majority (>90%) of these sites was located within promoter regions, indicating a relevance in the regulation of gene expression. Moreover, HCFC1 appears to be a major cofactor of THAP1 based on the ENCODE ChIP-seq and is even the highest ranked cofactor based on data retrieved from ChromNet (34) . These data is a good indication for an overall cobinding of THAP1 and HCFC1 which remains to be confirmed in dystonia-relevant, neuronal tissues.
Based on the important role of the THAP1-HCFC1 complex in gene regulation, we also functionally characterized for the first time three dystonia-causing missense variants (p.N136K, p.N136S and p.Y137C) within the HBM in the C-terminal region of THAP1. Importantly, we demonstrated loss of THAP1-HCFC1 heterodimerization in a yeast-two-hybrid system and confirmed the interaction by co-immunoprecipitation of endogenous HCFC1 with ectopically expressed full length THAP1 in a mammalian cell line (Fig. 1) . Although THAP1 directly binds to DNA at the THABS consensus motif, HCFC1 was not found to directly bind to DNA but needs THAP1 as a linker. Thus, we postulated that THAP1 variants abolishing HCFC1 binding result in a decrease of HCFC1 protein at THAP1-regulated promoter regions. To confirm THAP1-mediated binding of HCFC1 to the THAP1 target promoters of TOR1A, THAP1, RRM1 and BIRC5, we performed quantitative ChIP analyses. Dystonia-causing mutations affecting the residues N136 and Y137 in THAP1 significantly reduced HCFC1 recruitment to all four tested promoter regions, while none of the tested variants resulted in a significant reduction of THAP1 DNA binding. Interestingly, the THAP1 mutation p.Y137C seems to increase THAP1 binding to all promoter regions investigated. It might be possible that this variant increases either homodimerization or the binding to a (yet unknown) interaction partner and therefore increases DNAbinding affinity. Our data suggest that, while DNA binding of THAP1 is independent of HCFC1, HCFC1 recruitment to THAP1-target promoters is mediated by THAP1 (Fig. 3B) . We also demonstrated the functional relevance of HCFC1 as a cofactor for THAP1 activity in transcriptional regulation using siRNA-mediated knockdown of HCFC1 which is expected to have a similar effect as loss of binding of wildtype HCFC1 to THAP1 due to mutations in the HBM of THAP1. In this experiment, we showed a significant decrease of THAP1-mediated transcriptional repression on its own expression (Fig. 2B) , indicating that HCFC1 acts as a transcriptional cofactor of THAP1 in regulating gene expression. Along the same lines, siRNAmediated depletion of HCFC1 was previously shown to result in a decrease of RRM1 expression indicating an activation of RRM1 expression through a functional THAP1-HCFC1 complex (11) .
Further, we had screened dystonia patients for HCFC1 mutations in regions encoding domains important for the interaction with THAP1 but did not identify any disease-causing variant. Also, a frequent, non-synonymous variant (p.S1164P) was not enriched in our mostly German dystonia patients and thus does not represent a risk factor for dystonia. Of note, this variant is quite frequent (>50%) in Asians and Africans. More recently, both loss-and gain-of-function mutations affecting HCFC1 have been described as the genetic cause of neurodevelopmental disorders, characterized by severe intellectual disability and congenital anomalies (30, 35, 36) . The severe disease phenotype found in HCFC1 mutation carriers fits with the broad role of the encoded protein in gene regulation. On the other hand, the THAP1-HCFC1 regulatory complex represents only a subset of HCFC1 related functions compatible with absence of mutations in isolated dystonia patients.
In conclusion, HCFC1 is an essential cofactor of THAP1 and involved in the function of THAP1 activity as a transcriptional regulator. THAP1 binds to its target sequences and mediates HCFC1 recruitment. Dystonia-causing THAP1 mutations affecting the HBM lead to impaired THAP1-HCFC1 complex formation. Our results provide a better understanding of the THAP1-HCFC1 complex in transcriptional regulation and the role of THAP1 in the molecular pathology of dystonia.
Materials and Methods
Plasmid constructs
The full length open reading frame of THAP1 was amplified using a Marathon-Ready human fetal brain cDNA library (Clontech; Mountain View, CA, USA) and inserted into the pGADT7 (Clontech; Mountain View, CA, USA) and pFLAG-N3 (3xFLAG, Invitrogen) expression plasmids. Mutated THAP1 constructs for p.N136S (c.407A > G (20)), p.N136K (c.408C > G (21)) and p.Y137C (c.410A > G (22)) were generated using the QuikChangeV R Site-directed Mutagenesis Kit (Stratagene) and the full length THAP1-p pGADT7 expression plasmid as template. These mutated THAP1 constructs were also inserted into pFLAG-N3 (3xFLAG). The HCFC1 kelch domain was amplified with appropriate primers using a Marathon-Ready human fetal brain cDNA library (Clontech; Mountain View, CA, USA) and inserted into the pGBKT7 (Clontech; Mountain View, CA, USA) expression plasmid. All constructs were verified by direct sequencing (PE Applied Biosystems). The appropriate empty vectors were used as controls in all experiments.
Cell culture and transient transfection methods
Human embryonic kidney cells (HEK293) and neuroblastoma cells SH-SY5Y were cultured in Dulbecco's Modified Eagle Medium (PAA Laboratories, Austria) supplemented with 10-20% fetal bovine serum (FBS, Invitrogen) and 1% penicillinstreptomycin (Biozym). The cells were maintained at 37 C in a saturated humidified atmosphere containing 5% CO 2 . Transfection of cells with THAP1-coding constructs were performed with FuGENE-HD (Promega) according to the manufacture rs protocol while transfection with siRNA was performed with Lipofectamine (Invitrogen).
Westernblot
For Westernblot analysis, transiently transfected cells were harvested using a cell lifter, then transferred in a clean 1.5ml tube and lysed using RIPA buffer with PIC (1:250, Roche). After 5 min incubation the lysates were centrifuged to pellet the debris at 13,000xg for 10 min at 4 C. After denaturation at 95 C the proteins were separated on 8% or 10% Bis-Tris gels and transferred onto a nitrocellulose membrane. HCFC1 was visualized using an anti-HCFC1 antibody (1:500, Bethyl), wildtype and mutant 3xFLAG-tagged THAP1 was detected using anti-FLAG M2 antibody (1:1000, Sigma), anti-Neomycin antibody (1:500, Millipore) served as an expression control.
Yeast-two-hybrid
To investigate the dimerization of THAP1 and HCFC1 we performed yeast-two-hybrid assays. Therefore, the open reading frame of THAP1 was fused to the transcriptional activation domain of the GAL4 protein (AD, pGADT7 expression plasmid) while the HCFC1 kelch domain was fused to the DNA-binding domain (BD, pGKBT7 expression plasmid). In case of a direct interaction of THAP1 with HCFC1 the THAP1-AD construct will be recruited to specific promoters via the HCFC1-BD protein and activate reporter gene. While culturing yeast on -SD medium (-leucine, -tryptophan) does select for a successful cotransformation of the both expression plasmids, -4SD medium (-leucine, -tryptophan, -adenine, and -histidine) does only allow yeast growth if both fusion proteins interact and activate ADE2 and HIS3 reporter gene expression. Yeast cells (AH109) were transformed with wildtype or mutant THAP1 pGADT7 constructs and HCFC1 kelch domain pGKBT7 using lithium-acetate transformation. Briefly, yeast cells were grown in YPD full medium. Cells were harvested by centrifugation and after several washing steps resuspended in 250-300 ml TE buffer/lithium acetate reagent. Each transformation reaction contained 50 ml yeast cells, 300 ml polyethylenglycol reagent (100mM TE, 100 mM lithium acetate, 50% polyethylenglycol 4000), 50 mg salmon sperm DNA (Sigma), and 1 ml of each expression plasmid. The samples were carefully mixed and incubated at 30 C for 30 min followed 
Co-immunoprecipitation (co-IP)
To verify the results obtained by yeast-two-hybrid analysis we performed co-immunoprecipitation of THAP1 -HCFC1 protein complexes from HEK293 cell extracts. Therefore, cells were transiently transfected with wildtype or mutant THAP1 3xFLAG expression plasmids and harvested 24 h after transfection. 
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed with OneDay ChIP kit (Diagneode) according to the manufacturer's protocol to demonstrate THAP1 mediated binding of HCFC1 to the THAP1 promoter sequence. Briefly, HEK293 were transiently transfected with wildtype or mutant THAP1 3xFLAG or empty 3xFLAG expression plasmids. After 24 h chromatin was cross-linked by adding formaldehyde to a 1% final concentration. After nuclei extraction of transfected cells the chromatin was sonicated using Bioruptor pico. Sheared chromatin was incubated first with anti-HCFC1 (Bethyl) or anti-FLAG M2 (Sigma) antibodies and the chromatin-antibody complex was incubated with agarose beads. DNA was purified by DNA-binding slurry and then treated with proteinase K. PCR-grade water was used to elute DNA from slurry.
To determine the effect of THAP1 mutations on HCFC1 and DNA binding, we analyzed the precipitated DNA by quantitative real time PCR with qPCRBIO Probe Mix Hi-Rox (PCRBiosystems) for THAP1, TOR1A, RRM1 and BIRC5 promoter region with TaqMan probes (sequences available upon request) on the Abi prims 7300 system, input DNA was used as reference. All experiments were performed in triplicates and verified in at least two independent experiments. All measurements were performed in triplicates per qPCR. Data are given as mean and range of variation and were analyzed by unpaired t-test.
Bioinformatic analysis of THAP1/HCFC1 binding site overlap within genome segments
We used publicly available ChIP-seq data from the ENCODE Project (24) based on the K562 myelogenous leukemia cell line. We downloaded the narrowPeak bed files for THAP1 (ENCODE Accession ENCFF002CMU) and HCFC1 (ENCODE Accession ENCFF001VNH). Overlapping peaks in every single file were merged using bedtools (37) . To allocate the hits to different genomic states, we used two different databases: (a) The ENCODE ChromHMM Genome Segmentation data for K562 cells (38) . This data was generated by integrating ENCODE ChIP-seq, DNaseseq, and FAIRE-seq data using a Hidden Markov Model (HMM). In this dataset, 25 states were pre-defined and combined to differentiate ten kinds of genome segments using the ChromHMM machine-learning algorithm. (b) The refGene table at the UCSC Genome Browser (39, 40) , of which we extracted positional information for all refSeq transcripts. For our analyses, we defined three different genomic states based on their proposed function: Promoters, gene bodies, and intergenic. General promoter regions were defined by combining active and inactive promoter segments from the ChromHMM Genome Segmentation data. Those regions subtracted from refGene transcripts were defined as gene bodies. The remaining part of the genome was considered to be intergenic. Next, bedtools was used to generate one file with overlapping THAP1/HCFC1 peaks and one file with THAP1 peaks which do not overlap with HCFC1 peaks. For both files overlap with promoter region, gene bodies and intergenic regions was counted.
Mutational analysis of HCFC1 in patients with dystonia
We screened Exons 1-9 and Exon 17 (in four overlapping parts) for mutations in 156 dystonia patients (91 man, mean age: 37 6 13 years, mean age at onset: 17 6 8.5 years) by Sanger sequencing. Primer sequences are available upon request. The study was approved by the local ethics committee and all participants gave written informed consent. All patients were negative for mutations in TOR1A, THAP1, or GNAL. A positive family history was known for 46 patients. Diagnoses included generalized (n ¼ 45), segmental (n ¼ 32), and focal (n ¼ 79; cervical dystonia, writer's cramp, blepharospasm, spasmodic dysphonia or musician's dystonia) dystonia. All patients were examined by a movement disorder specialist according to standard protocols.
